

The Biosynthesis of 5,6-Dimethylbenzimidazole from 6,7-Di[¹⁴C]methyl-8-ribityl-lumazine

By SHEUE-HON LU, MARY F WINKLER, and WILLIAM L ALWORTH*

(Department of Chemistry, Tulane University, New Orleans, Louisiana 70118)


Summary Degradation of [¹⁴C]-5,6-dimethylbenzimidazole isolated from biosynthetic vitamin B₁₂ indicated that the 4,5-dimethyl-1,2-phenylene unit was formed by a bimolecular condensation of added 6,7-di[¹⁴C]methyl-8-ribityl-lumazine precursor

RECENT experimental results indicate that the biosyntheses of riboflavin and of the 5,6-dimethylbenzimidazole (DBI) moiety of vitamin B₁₂ are connected. Labeled compounds tested as precursors of DBI¹⁻³ led to incorporation efficiencies and patterns that paralleled the results of investigations into the origin of ring A of riboflavin⁴. Renz has also reported that [¹⁴C]riboflavin was efficiently converted into [¹⁴C]DBI in cell preparations of *P. shermanii*⁵. We report that 6,7-di[¹⁴C]methyl-8-ribityl-lumazine is an effective precursor of the DBI moiety of vitamin B₁₂, and that the labelling pattern within the resulting [¹⁴C]DBI is consistent with its biosynthesis *via* a bimolecular 6,7-di[¹⁴C]methyl-8-ribityl-lumazine condensation.

6,7-Dimethyl-8-ribityl-lumazine labelled with ¹⁴C in the methyl carbons was synthesized according to Plaut's procedure⁶. It was purified by column chromatography and crystallized from 80% EtOH, m p 280—283° (decomp). The identity and purity were checked by elemental analysis, u v spectroscopy, and paper chromatography⁷.

100.2 mg (2.07 × 10⁶ d p m) of 6,7-di[¹⁴C]methyl-8-ribityl lumazine was added to a *P. shermanii* culture that had been incubated anaerobically for 4 days. After 5 more days of aerobic growth, the cells were harvested, and the vitamin B₁₂ was purified (36 mg, 1.9 × 10⁶ d p m). The growth conditions and the procedures used to purify the vitamin B₁₂ have been described^{2,8}. The [¹⁴C]DBI sample obtained by hydrolysis of the vitamin B₁₂ was diluted with unlabelled DBI, purified, and the specific activity determined. The incorporation data were then corrected to take into account the observed yield of DBI (59%) from hydrolysis of the vitamin B₁₂.

The labelling pattern within the DBI was established by determining the specific activities of chemical degradation products in a liquid scintillation counter. The conversion of DBI into 1,2-dibenzamido-4,5-dimethylbenzene with release of the C-2 carbon as CO₂ has been described⁹. Determination of the labelling pattern within the remainder of the DBI molecule was based upon Kuhn-Roth oxidation



(reaction 1) Distribution of the label within the AcOH was established by Roseman's procedure⁹. Roseman's degradation yields benzimidazole containing C-1 of AcOH [C-5(6) of DBI] and releases C-2 of AcOH [C-8(9) of DBI] as CO₂. The distribution of label within the imidazole-4,5-dicarboxylic acid (IDC) was determined by decarboxylating the IDC to imidazole [C-2,3a(7a) of DBI] and CO₂ [C-4(7) of DBI]. This degradative scheme has been reported in greater detail³.

About 9% of the ¹⁴C added to the culture was recovered as radioactive vitamin B₁₂. The specific activity of the purified DBI indicated that about 75% of the total vitamin B₁₂ activity was present in the DBI moiety. The specific activities of the degradation products established that the label within the biosynthetic DBI was completely confined to C-4(7) and to C-8(9). 44% of the DBI label was located at the equivalent C-4 and C-7 positions, and 38% of the label was located at the equivalent C-8 and C-9 positions. Degradation products representing the other carbon atoms

were each found to contain less than 1% of the total DBI label. The methyl carbons of 6,7-di[¹⁴C]methyl-8-ribityl-lumazine are therefore specific biosynthetic precursors of carbon atoms C-4(7) and C-8(9) of DBI.

Plaut established that 6,7-di[¹⁴C]methyl-8-ribityl-lumazine is converted into [¹⁴C]riboflavin specifically labelled in the methyl carbons and at C-5 and C-8.⁶ The results reported here therefore indicate that the 4,5-dimethyl-1,2-phenylene unit of DBI is derived by the same type of bimolecular 6,7-dimethyl-8-ribityl-lumazine condensation as is involved in the biosynthesis of riboflavin.¹⁰ This observation, when combined with the experimental results cited earlier,^{1-3,5} establishes that Woolley was correct when

he suggested that the biosyntheses of riboflavin and of DBI were connected.¹¹ It remains, however, to be definitively established that riboflavin is an obligatory intermediate in the biosynthesis of DBI as suggested by Renz.⁵ Possibly related but branching pathways lead to the formation of both riboflavin and DBI directly from the common 6,7-dimethyl-8-ribityl-lumazine precursor.

This research was supported by a research grant from the National Institute of Arthritis and Metabolic Diseases and by a supporting grant from the Bureau of Health Professions Education, and Manpower Training of the National Institutes of Health.

(Received, November 19th, 1970; Com. 2001.)

¹ P. Renz and K. Reinhold, *Angew. Chem. Internat. Edn.*, 1967, **6**, 1083.

² W. L. Alworth, H. N. Baker, D. A. Lee, and B. A. Martin, *J. Amer. Chem. Soc.*, 1969, **91**, 5662.

³ W. L. Alworth, H. N. Baker, M. F. Winkler, A. M. Keenan, G. W. Gokel, and F. L. Wood III, *Biochem. Biophys. Res. Comm.*, 1970, **40**, 1026.

⁴ G. W. E. Plaut, *J. Biol. Chem.*, 1954, **211**, 111; S. N. Ali and U. A. S. Al-Khalidi, *Biochem. J.*, 1966, **98**, 182.

⁵ P. Renz, *F.E.B.S. Letters*, 1970, **6**, 187.

⁶ G. W. E. Plaut, *J. Biol. Chem.*, 1963, **238**, 2225.

⁷ G. F. Maley and G. W. E. Plaut, *J. Biol. Chem.*, 1959, **234**, 641; C. H. Winestock and G. W. E. Plaut, *J. Org. Chem.*, 1961, **26** 4456.

⁸ W. L. Alworth and H. N. Baker, *Biochem. Biophys. Res. Comm.*, 1968, **30**, 496.

⁹ S. Roseman, *J. Amer. Chem. Soc.*, 1953, **75**, 3854.

¹⁰ R. A. Harvey and G. W. E. Plaut, *J. Biol. Chem.*, 1966, **241**, 2120.

¹¹ D. W. Woolley, *J. Experimental Medicine*, 1951, **93**, 13.